Company Performance Metrics
Laxman Desai: President/CEO & Founder
Lise Vanderkelen: Dep. Head Pharma Services
Toxikon Corp. was founded as Cambridge Diagnostics in 1977 and reincorporated to its current namesake in 1982 by Dr. Laxman Desai, president and CEO.
Prior to establishing the company, Dr. Desai managed oncology drug research programs at the Dana-Farber Cancer Institute in Boston. It is through his expertise that Toxikon became established in
life sciences and has continued to advance innovations in the pharmaceutical, biotechnology, and medical device industries for more than 30 years.
Throughout its history, Toxikon has evolved to meet the challenges of life science industries. In 1987, Toxikon acquired the former American Biogenics, Inc., of Woburn, MA. This facility was part of the National Toxicology Program, and Toxikon expanded its toxicology and analytical capabilities from 1987 through 1995.
In 1995, Toxikon relocated to its current location in Bedford, MA, an 80,000-square-foot facility that allowed the contract research organization to further expand its testing services for medical device, biotech, and pharmaceutical markets dedicated to research and development, GLP, and GMP projects. In 2005, Toxikon purchased the former SunOpta Ingredients Group facility directly next door to its Bedford headquarters, transforming it into more than 45,000 square feet of additional laboratory space and creating a campus-style setting and space for large animal models and additional instrumentation for bioanalytical support services.
